Lucid Diagnostics Inc. (LUCD)
NASDAQ: LUCD · Real-Time Price · USD
1.100
-0.030 (-2.65%)
At close: May 12, 2025, 4:00 PM
1.149
+0.049 (4.45%)
After-hours: May 12, 2025, 7:57 PM EDT
Company Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States.
The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.
Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients.
The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Oct 14, 2021 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 72 |
| CEO | Lishan Aklog |
Contact Details
Address: 360 Madison Avenue, 25th Floor New York, New York 10017 United States | |
| Phone | 917 813 1828 |
| Website | luciddx.com |
Stock Details
| Ticker Symbol | LUCD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $14.00 |
| CIK Code | 0001799011 |
| CUSIP Number | 54948X109 |
| ISIN Number | US54948X1090 |
| Employer ID | 82-5488042 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lishan Aklog M.D. | Chairman and Chief Executive Officer |
| Shaun M. O'Neill M.B.A. | President and Chief Operating Officer |
| Michael Adam Gordon | General Counsel and Secretary |
| Dr. Sanford D. Markowitz M.D., Ph.D. | Co-Founder and Strategic Advisor |
| Dr. Joseph Willis M.D. | Co-founder and Strategic Advisor |
| Dr. Amitabh Chak M.D. | Co-Founder and Strategic Advisor |
| Helen Moinova Ph.D. | Co-Founder and Strategic Advisor |
| Dr. Brian J. deGuzman M.D. | Chief Technology and Compliance Officer |
| Dr. Suman M. Verma M.D., Ph.D. | Chief Scientific Officer |
| Matthew Riley | Director of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2025 | 8-K | Current Report |
| Apr 18, 2025 | PRE 14A | Other preliminary proxy statements |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 10, 2025 | 424B5 | Filing |
| Apr 10, 2025 | 8-K | Current Report |
| Apr 9, 2025 | 424B5 | Filing |
| Mar 25, 2025 | 8-K | Current Report |